Vascepa is a prescription drug used to treat high levels of triglycerides in the blood. The active ingredient in Vascepa is icosapent ethyl. The drug is manufactured by Amarin Corporation and was approved by the FDA in 2012. According to the sources provided, Vascepa has been facing challenges with generic competition and patent expiration.

In September 2020, the FDA denied Amarin Corporation's request for five years of exclusivity for Vascepa [2]. This means that generic versions of the drug could enter the market sooner than expected. However, it is unclear when the generic versions of Vascepa will become available.

DrugPatentWatch.com [1] indicates that the earliest generic version of Vascepa could be available is in September 2021. However, this date is subject to change, and it is not guaranteed that a generic version of Vascepa will be available at that time.

It is important to note that even when a generic version of a drug becomes available, it may not necessarily be significantly more affordable than the brand-name version. Healthline.com [3] explains that the cost of a generic drug can vary depending on the manufacturer, the pharmacy, and the insurance plan. In some cases, the generic version may only be slightly less expensive than the brand-name version.

In conclusion, while a generic version of Vascepa may become available in the near future, it is uncertain when this will happen. Additionally, the cost of the generic version may not be significantly more affordable than the brand-name version. Patients should consult with their healthcare provider and insurance company to determine the most cost-effective option for their individual needs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fiercepharma.com/regulatory/amarin-s-future-dims-further-as-fda-nixes-5-year-vascepa-exclusivity
[3] https://www.healthline.com/health/drugs/vascepa